2017-2021 Йилларда Ўзбекистон Республикасида Онкология Хизматини Янада Ривожлантириш Ва Аҳолига Онкологик Ёрдам Кўрсатишни Такомиллаштириш Чора-Тадбирлари Тўғрисида

Objectives

Uzbekistan’s 2017–2021 programme seeks to further develop a unified, vertically integrated oncology service and improve the quality, accessibility and international alignment of cancer care for the population.[1][2]Its overarching aim is to reduce the cancer burden through prevention, screening, earlier diagnosis, modern treatment, rehabilitation and supportive care, with intended improvements in cancer mortality, survival and patients’ quality of life.[1][3][4]

• Strengthen cancer prevention through public information, healthier lifestyles, risk-factor reduction and effective prevention programmes.[5][6][7]
• Improve screening and early diagnosis, including cytological screening in primary care and programmes for breast, cervical and colorectal cancers.[8][9][10]
• Expand access to accurate diagnostics, modern clinical protocols and high-technology specialised treatment, including molecular-genetic methods, interventional radiology, endovascular surgery, targeted therapy and immunotherapy.[11][5][12][13]
• Modernise oncology infrastructure through construction, reconstruction, capital repairs, equipment procurement, technical servicing and provision of medicines, reagents, consumables and inventory.[14][15][16]
• Develop the oncology workforce through specialist education, retraining, overseas placements, seminars and qualification improvement for oncologists, radiologists, laboratory personnel, nurses and primary-care staff.[17][18][19]
• Advance domestic oncology research on carcinogenesis, tumour biology, epidemiology, risk factors and new anticancer medicines, while applying international scientific and clinical experience.[20][21][22]
• Provide medical, psychological and palliative support for people with advanced or incurable cancer, including an intended annual reach of 8,000 patients and interregional hospice development.[23][24][25]

Implementation

The programme combines national institutional restructuring, three-level service organisation, investment in facilities and equipment, workforce development, clinical standardisation, cancer surveillance and multi-agency financing.[26][20][3]Delivery centres on the Republican Specialised Scientific and Practical Medical Centre for Oncology and Radiology, its regional branches and city oncology dispensaries, alongside dedicated Cancer Prevention and Experimental Oncology Centres.[27][20][28]

• Coordinate implementation through the Ministry of Health, Ministry of Finance, Ministry of Economy and other relevant national bodies, with regional and city authorities supporting local delivery and infrastructure projects.[29][30][31]
• Organise oncology care through a vertically integrated, three-level system linking primary healthcare, district and city medical associations, regional branches and the national specialised centre.[1][26][32]
• Assign the Cancer Prevention Centre methodological and coordinating responsibilities for prevention, screening, a unified cancer-patient information base and epidemiological monitoring.[33]Assign the Experimental Oncology Centre responsibility for research on carcinogenesis, malignant-tumour mechanisms and domestic anticancer medicines.[33]
• Implement screening pathways, diagnostic and treatment standards, clinical protocols and screening algorithms, supported by staff seminars and training across all levels of care.[11][34][4][35]
• Maintain a cancer registry and use departmental medical statistics, screening data and epidemiological monitoring to inform prevention programmes, staffing decisions and assessment of early detection.[20][33][4]
• Equip specialised and territorial institutions with mammography, endoscopic, molecular-genetic, immunological, magnetic resonance imaging, computed tomography, radiotherapy and other high-technology equipment, alongside maintenance and spare-parts provision.[36][6][37][16]
• Construct, reconstruct and repair national and regional oncology facilities between 2017 and 2020, using approved project parameters, design-and-cost documentation, expert review and authorised address lists.[38][39][40]
• Establish inter-district oncology facilities and territorial palliative-care services, including four interregional hospices in Tashkent, Fergana, Samarkand and Urgench, with up to 50 beds each.[12][25]
• Strengthen international engagement through cooperation with foreign oncology centres, specialist exchanges, joint research, congresses and potential membership of the International Union Against Cancer and the European Society for Medical Oncology.[41][42][43]
• Mobilise state-budget appropriations, local resources, off-budget funds, concessional loans, international-financial-organisation credits, grants, charitable contributions and institutional resources.[31][44][45][16]

Specified monitoring mechanisms include cancer registration, epidemiological surveillance, screening activity, medical statistics, evaluation of prevention-information activities and selected performance targets.[8][46][9]Targets include increasing early detection from 10% to 15% in one activity, raising early breast-cancer detection from 4% to 10% and early-stage breast-cancer detection from 10% to 15%, and increasing opioid-analgesic access from 33.2% to 90%.[47][32][37]The source does not specify a comprehensive indicator matrix, common reporting timetable, independent evaluation design or public accountability framework across the whole programme.[20][34][35]

Monitoring & Evaluation

Monitoring arrangements centre on cancer registration, screening, medical statistics and administrative oversight, but the programme does not set out a comprehensive results framework with consistently defined indicators, reporting intervals or independent evaluation arrangements.[20][8][33]

• Maintain a cancer registry and unified information base for patients with malignant neoplasms, administered through the specialised oncology and radiology centre and used to monitor the epidemiological situation.[20][8][33]
• Use screening examinations, annual medical examinations, cytological testing in primary healthcare, laboratory diagnostics and risk-group screening to monitor early detection and diagnostic coverage.[48][9][10]
• Track stated outcome measures including raising cancer early detection from 10% to 15%, increasing breast-cancer detection from 4% to 10%, increasing early-stage breast-cancer detection from 10% to 15%, improving diagnosis of oesophageal, stomach and colorectal cancers by 10–15%, and increasing opioid-analgesic coverage from 33.2% to 90%.[48][32][9][37]
• Assess cancer-prevention programmes using scientifically based methods, evaluate information and education activities, and use pilot-project results to inform possible expansion to other regions.[20][46][10]
• Update reporting forms and information systems and apply unified approaches to statistical work across oncology institutions.[8]
• Use expected improvements in diagnostic quality, earlier detection, treatment outcomes, laboratory capacity, cancer mortality, survival and access to care as broad implementation results.[1][5][9]
• Assign implementation oversight to senior national officials, including the Deputy Prime Minister and Presidential Adviser in one decision, and the Prime Minister and a State Adviser to the President in another.[38][49]
• Apply administrative controls through approved staffing structures, equipment parameters, design-and-cost documentation, expert review and authorised project address lists.[50][40][51][16]

Several extracts identify responsible ministries, oncology institutions, implementation periods and operational outputs, such as training, facility works and equipment provision, but do not specify a consistent indicator matrix, data-quality process, public reporting timetable, evaluation design or formal sanctions for non-performance.[6][18][30][19]

Costing & Financing

Financing combines state-budget resources with off-budget funds, local budgets, international credits and concessional loans, grants, charitable contributions, institutional resources and donor support; however, the extracts do not provide a single consolidated and fully costed programme budget or a quantified funding-gap assessment.[29][5][31][16]

• Finance construction, reconstruction, capital repairs, equipment and material-technical development through state-budget allocations, including an off-budget Ministry of Finance fund for educational and medical infrastructure.[38][44][52]
• Mobilise concessional credits and loans, grants from foreign states and international financial organisations, other extra-budgetary funds, charitable donations and institutional resources.[29][53][31]
• Review annual funding requirements for the 2017–2021 oncology programme during preparation of the national state budget.[31]
• Support screening equipment, medicines, reagents, consumables, staff training, palliative care, facility works and high-technology diagnostic and treatment equipment through the listed funding sources.[14][9][24][16]
• Record specified allocations in Uzbekistani soms and United States dollars, although several table extracts do not reliably link each amount to an activity or funding source because of OCR and table-extraction limitations.[5][6][12][53]
• Determine project costs after preparing and obtaining expert review of design-and-estimate documentation before tendering for infrastructure works.[52]

Economic assumptions, unit costs, expenditure phasing, financing shares and funding gaps are generally not specified; where figures appear in tables, their labels or monetary units are sometimes incomplete or uncertain in the supplied extract.[17][54][40]